Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Not Available
III
Iams, Wade
NCT03703297
VICCTHO1901

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: